Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
|Videos|June 6, 2017
Tripathy Discusses a Study of Talazoparib in BRCA-Mutated Advanced Breast Cancer
Author(s)Debu Tripathy, MD
Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the phase II ABRAZO study of talazoparib following platinum or multiple cytotoxic regimens in advanced breast cancer patients with germline <em>BRCA</em> 1/2 mutations during the 2017 ASCO Annual Meeting.
Advertisement
Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the phase II ABRAZO study of talazoparib (BMN-673) following platinum or multiple cytotoxic regimens in advanced breast cancer patients with germlineBRCA1/2 mutations during the 2017 ASCO Annual Meeting.
Advertisement
Related to this article
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
The phase 2 NRG-BR002 failed to improve outcomes with targeted radiotherapy to oligometastases; the phase 3 portion will not proceed.
ER status and HER2DX score predict complete response to neoadjuvant THP in HER2-positive breast cancer, guiding smarter, less intensive chemo selection.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
Durability of PFS and OS Benefit vs. Historical Control
3
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
4
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
5